Association between Class III Obesity (BMI of 40–59 kg/m2) and Mortality: A Pooled Analysis of 20 Prospective Studies

Summary

Background The prevalence of class III obesity (body mass index [BMI]≥40 kg/m2) has increased dramatically in several countries and currently affects 6% of adults in the US, with uncertain impact on the risks of illness and death. Using data from a large pooled study, we evaluated the risk of death, overall and due to a wide range of causes, and years of life expectancy lost associated with class III obesity. Methods and Findings In a pooled analysis of 20 prospective studies from the United States, Sweden, and Australia, we estimated sex- and age-adjusted total and cause-specific mortality rates (deaths per 100,000 persons per year) and multivariable-adjusted hazard ratios for adults, aged 19–83 y at baseline, classified as obese class III (BMI 40.0–59.9 kg/m2) compared with those classified as normal weight (BMI 18.5–24.9 kg/m2). Participants reporting ever smoking cigarettes or a history of chronic disease (heart disease, cancer, stroke, or emphysema) on baseline questionnaires were excluded. Among 9,564 class III obesity participants, mortality rates were 856.0 in men and 663.0 in women during the study period (1976–2009). Among 304,011 normal-weight participants, rates were 346.7 and 280.5 in men and women, respectively. Deaths from heart disease contributed largely to the excess rates in the class III obesity group (rate differences = 238.9 and 132.8 in men and women, respectively), followed by deaths from cancer (rate differences = 36.7 and 62.3 in men and women, respectively) and diabetes (rate differences = 51.2 and 29.2 in men and women, respectively). Within the class III obesity range, multivariable-adjusted hazard ratios for total deaths and deaths due to heart disease, cancer, diabetes, nephritis/nephrotic syndrome/nephrosis, chronic lower respiratory disease, and influenza/pneumonia increased with increasing BMI. Compared with normal-weight BMI, a BMI of 40–44.9, 45–49.9, 50–54.9, and 55–59.9 kg/m2 was associated with an estimated 6.5 (95% CI: 5.7–7.3), 8.9 (95% CI: 7.4–10.4), 9.8 (95% CI: 7.4–12.2), and 13.7 (95% CI: 10.5–16.9) y of life lost. A limitation was that BMI was mainly ascertained by self-report. Conclusions Class III obesity is associated with substantially elevated rates of total mortality, with most of the excess deaths due to heart disease, cancer, and diabetes, and major reductions in life expectancy compared with normal weight.

Related articles

• Why art? The role of arts in arts and health

  This article addresses the complex relationship between the arts and health, questioning the role of the arts in improving mental and physical well-being. It explores various theoretical constructs and empirical evidence while emphasizing the need for a coherent definition of art to understand its effects on health.

• Oncogenesis

  This article examines the role of p52-ZER6 in the metabolic reprogramming of tumor cells, highlighting its impact on the pentose phosphate pathway and tumor progression. The study provides insights into the biochemical processes involved and points to potential therapeutic targets for cancer treatment.

• From library to landscape: integrative annotation workflows for compound libraries in drug repurposing

  This article details the creation of two automated annotation workflows designed for the integration of chemical and bioactivity data from various public repositories to support drug repurposing projects.

• Comprehensive Hemodialysis and Nephrology Lecture

  This document is a detailed lecture series on hemodialysis and nephrology, discussing the fundamentals of dialysis, historical milestones, advanced modalities, and complications associated with the treatment, aiming to enhance understanding for medical trainees and professionals.

• ShiftScan: A tool for rapid analysis of high-throughput differential scanning fluorimetry data and compound prioritization

  This document presents ShiftScan, a standalone tool designed for the rapid analysis of differential scanning fluorimetry (DSF) data in drug discovery, enabling efficient filtering and prioritization of compounds based on thermal transition patterns. It aims to assist researchers in managing large datasets and improving the identification of potential drug candidates.